|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500099480 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-25 08:08:45 |
|
注册时间: Date of Registration: |
2025-03-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
新型血栓标志物在Stanford A型主动脉夹层患者中预后价值的临床研究 |
|
Public title: |
Clinical Study on the Prognostic Value of Novel Thrombus Biomarkers in Patients with Stanford Type A Aortic Dissection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新型血栓标志物在Stanford A型主动脉夹层患者中预后价值的临床研究 |
|
Scientific title: |
Clinical Study on the Prognostic Value of Novel Thrombus Biomarkers in Patients with Stanford Type A Aortic Dissection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孟凡琦 |
研究负责人: |
孟凡琦 |
|
Applicant: |
Fanqi Meng |
Study leader: |
Fanqi Meng |
|
申请注册联系人电话: Applicant telephone: |
+86 159 5923 2882 |
研究负责人电话:
Study leader's |
+86 159 5923 2882 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
mengfq0927@126.com |
研究负责人电子邮件: Study leader's E-mail: |
mengfq0927@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省厦门市湖里区金山路2999号 |
研究负责人通讯地址: |
福建省厦门市湖里区金山路2999号 |
|
Applicant address: |
No. 2999, Jinshan Road, Huli District, Xiamen City, Fujian Province |
Study leader's address: |
No. 2999, Jinshan Road, Huli District, Xiamen City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
361000 |
研究负责人邮政编码: Study leader's postcode: |
361000 |
|
申请人所在单位: |
厦门大学附属心血管病医院 |
||
|
Applicant's institution: |
Xiamen Cardiovascular Hospital of Xiamen University |
||
|
研究负责人所在单位: |
厦门大学附属心血管病医院 |
||
|
Affiliation of the Leader: |
Xiamen Cardiovascular Hospital of Xiamen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)医伦科第(11)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
厦门大学附属心血管病医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Xiamen Cardiovascular Hospital of Xiamen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-06-06 00:00:00 | ||
|
伦理委员会联系人: |
王仁霁 |
||
|
Contact Name of the ethic committee: |
Renji Wang |
||
|
伦理委员会联系地址: |
福建省厦门市湖里区金山路2999号 |
||
|
Contact Address of the ethic committee: |
2999 Jinshan Road, Huli District, Xiamen, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 158 8028 6760 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
厦门大学附属心血管病医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiamen Cardiovascular Hospital of Xiamen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市湖里区金山路2999号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 2999, Jinshan Road, Huli District, Xiamen City, Fujian Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
A型主动脉夹层 |
||||||||||||||||||||||
|
Target disease: |
Type A aortic dissection |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
本研究拟收集A型主动脉夹层患者中新血栓标志物(TM、t-PAIC、TAT、PIC)的数据,明确外科手术前后凝血及纤溶系统变化,同时结合传统生物标志物,提高危险分层及预后评估的准确性,为及时的临床干预提供依据,改善患者的预后 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to collect data on new thrombus biomarkers(TM, t-PAIC, TAT, PIC) in patients with type A aortic dissection, elucidating the changes in coagulation and fibrinolytic systems before and after surgical intervention. By integrating traditional biomarkers, we seek to enhance the accuracy of risk stratification and prognostic assessment, thereby providing a basis for timely clinical interventions that can improve patient outcomes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄>=18岁,就诊于厦门大学附属心血管病医院临床诊断为A型主动脉夹层,并行急诊外科手术的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients aged 18 years and older, who were diagnosed with type A aortic dissection at Xiamen University Affiliated Cardiovascular Hospital and undergo emergency surgical intervention. |
||||||||||||||||||||||
|
排除标准: |
从症状出现至入院超过48小时的患者,合并有急性重症感染、恶性肿瘤、肝硬化、终末期肾病多系统疾病等预期生存期不明确疾病,以及拒绝参加的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients who have experienced symptoms for more than 48 hours prior to hospitalization, and who present with conditions such as acute severe infections, malignant tumors, liver cirrhosis, end-stage renal disease, or other multi-system diseases with uncertain prognosis, as well as those who refuse participation in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-01 00:00:00至 To 2026-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-04-01 00:00:00 至 To 2026-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
eCRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
eCRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |